Related Experiment Video
Updated: Feb 15, 2026

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
Enhanced YAP expression leads to EGFR TKI resistance in lung adenocarcinomas
Ting-Fang Lee1, Yu-Chi Tseng2, Phung Anh Nguyen3,4
1Institute of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan.
Abstract:
Epidermal growth factor receptor (EGFR) mutation is prevalently expressed in lung adenocarcinoma cases and acts as one of the major driving oncogenes. EGFR tyrosine kinase inhibitors (TKIs) have been used in patients with EGFR-mutant as an effective targeted therapy in lung adenocarcinoma, but drug resistance and tumor recurrence inevitably occurs. Recently, Yes-associate protein (YAP) has been reported to promote multiple cancer cell properties, such as promoting cell proliferation, epithelial-mesenchymal transition and drug resistance. This study investigated the roles of YAP in TKI-resistant lung adenocarcinoma. In TKI-sensitive cells, enhanced YAP expression leads to TKI resistant. Also, upregulated YAP expression and activation were detected in long-term TKI-induced resistant cells. With reduced YAP expression using shRNA or YAP inhibitors, TKI-resistant cells become TKI-sensitive. reduced xenograft tumor size in nude mice and Moreover, combined EGFR TKI and a YAP inhibitor, statin, prolonged survival among lung cancer patients analyzed by Taiwan National Health Insurance Research database. These observations revealed the importance of YAP in promoting TKI-resistance and combined YAP inhibition can be a potential therapy delaying the occurrence of TKI-resistance in lung adenocarcinoma.
Insights
Yes-associated protein (YAP) drives resistance to EGFR tyrosine kinase inhibitors (TKIs) in lung adenocarcinoma. Inhibiting YAP can re-sensitize resistant cells and potentially delay resistance, offering a new therapeutic strategy.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Epidermal growth factor receptor (EGFR) mutations are key drivers in lung adenocarcinoma, with EGFR tyrosine kinase inhibitors (TKIs) offering targeted therapy.
- Acquired resistance to TKIs and subsequent tumor recurrence remain significant challenges in treating EGFR-mutant lung adenocarcinoma.
- Yes-associated protein (YAP) is implicated in promoting cancer progression, including proliferation, epithelial-mesenchymal transition, and drug resistance.
Purpose of the Study:
- To investigate the role of YAP in the development and maintenance of TKI resistance in lung adenocarcinoma.
- To evaluate the therapeutic potential of YAP inhibition, alone or in combination with EGFR TKIs, for overcoming TKI resistance.
Main Methods:
- Assessed YAP expression and activation in TKI-sensitive and TKI-resistant lung adenocarcinoma cell lines.
- Utilized shRNA and YAP inhibitors to reduce YAP expression and activity in resistant cells.
- Evaluated the effect of YAP inhibition on TKI sensitivity in vitro and in xenograft models.
- Analyzed patient survival data from the Taiwan National Health Insurance Research database for combined EGFR TKI and YAP inhibitor (statin) therapy.
Main Results:
- Enhanced YAP expression was found to induce TKI resistance in sensitive lung adenocarcinoma cells.
- Upregulated YAP expression and activation were observed in cells that developed long-term TKI resistance.
- Reducing YAP expression or inhibiting its activity restored sensitivity to TKIs in resistant cells.
- Combined EGFR TKI and YAP inhibition (statin) significantly reduced tumor size in xenografts and prolonged patient survival.
Conclusions:
- YAP plays a critical role in promoting resistance to EGFR TKIs in lung adenocarcinoma.
- Targeting YAP, in combination with EGFR TKIs, represents a promising therapeutic strategy to overcome TKI resistance and improve patient outcomes.
- YAP inhibition may be a valuable approach to delay the onset of TKI resistance in lung adenocarcinoma patients.
More Related Videos
06:03Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression
Published on: January 19, 2019
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
Related Concept Videos
Lung Capacity
Resistivity
Resistance
Phase-lead and Phase-lag Controllers
Self-Evaluation: Self-Enhancement and Self-Verification
Equivalent Resistance